BioFactura Announces Activation of a $15.9M Contract Option for its Smallpox Biodefense Therapeutic
Frederick, Maryland, July 14, 2022: BioFactura Inc. (“BioFactura”) today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance development of an antibody cocktail therapeutic for the treatment of smallpox. This funding is part of BioFactura’s prime contract valued at up to $68.2 million for the … Continue reading